Evaluation of Adhesion and Dermal Tolerability of EMSAM

NCT00531596 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: EMSAM (Selegiline Transdermal System) 6mg/24Hr
DRUG: EMSAM (Selegiline Transdermal System) 9mg/24Hr
DRUG: EMSAM (Selegiline Transdermal System) 12mg/24hr

Sponsor

Somerset Pharmaceuticals